阅读说明：本技术 一种检测布鲁菌病治疗效果的标志物及其应用 (Marker for detecting treatment effect of brucellosis and application thereof ) 是由 薛继华 李家斌 郜玉峰 尹华发 程君 许夕海 于 2019-09-29 设计创作，主要内容包括：本发明涉及医药技术领域,具体是指一种检测布鲁菌病治疗效果的标志物及其应用。本发明的目的在于提供嗜酸性粒细胞水平在预测布鲁菌病治疗效果中的用途,具体地涉及通过检测嗜酸性粒细胞计数及百分比评估布鲁菌病患者的治疗效果。一种检测布鲁菌病治疗效果的标志物,所述标志物的为嗜酸性粒细胞。本发明首次揭示了：在布鲁菌病患者中嗜酸性粒细胞计数及比例下调,予以抗感染治疗后嗜酸性粒细胞计数及比例逐渐恢复。(The invention relates to the technical field of medicines, in particular to a marker for detecting the treatment effect of brucellosis and application thereof. The invention aims to provide application of eosinophil level in predicting therapeutic effect of brucellosis, and particularly relates to evaluation of therapeutic effect of brucellosis patients by detecting eosinophil count and percentage. A marker for detecting the treatment effect of brucellosis, wherein eosinophils are adopted as the marker. The invention discloses for the first time: eosinophil count and proportion are reduced in brucella patients, and eosinophil count and proportion are gradually recovered after anti-infection treatment.)

1. A marker for detecting the treatment effect of brucellosis is characterized in that: the marker is eosinophil.

2. The marker of claim 1, wherein: evaluating the treatment effect of the brucellosis patient according to the detected eosinophil count and percentage; the disease condition of the brucella patients is predicted according to the content or the change trend of the content of the blood eosinophils.

3. Use of the marker of claim 1 for detecting the effect of treatment and predicting the condition of patients with brucellosis.

4. Use of a reagent for detecting the marker of claim 1 for the preparation of a reagent for evaluating the effect of treatment or predicting the condition of a patient with brucella.

5. Use of a method for detecting a marker according to claim 1 for assessing the efficacy of a treatment or predicting the condition of a patient suffering from brucella.

6. Use according to claim 4 or 5, characterized in that: the detection marker is the detected eosinophil count and percentage.

7. Use according to claim 4 or 5, characterized in that: the treatment effect refers to whether the body temperature of the patient is normal or not.

8. Use according to claim 4 or 5, characterized in that: the disease condition of the patient with brucella is predicted according to the content of blood eosinophils or the change trend of the content of the blood eosinophils.

Technical Field

The invention relates to the technical field of medicines, in particular to a marker for detecting the treatment effect of brucellosis and application thereof.

Background

Brucellosis (Brucellosis) is a natural epidemic disease, and is a bacterial infectious disease caused by Brucella and mainly derived from human and animals. Over the 21 st century, brucellosis in our country has shown a tendency to re-epidemic, with the affected areas expanding from northern pasturing areas to adjacent grassland and agricultural areas, and then to southern coastal and southwest areas. Brucella can invade human body through multiple transmission ways, can cause the hyperplasia of the reticuloendothelial system of the whole body, and is accompanied with the damage of multiple systems such as nerve, circulation, reproduction, immunity and the like, thereby causing the loss of the labor capacity of patients, and even becoming a main factor restricting the economic development in partial areas.

Brucella is an intracellular parasitic bacterium which is mainly propagated in reticuloendothelial system cells of a human body, and lack of proper treatment in an acute stage can cause Brucella to be colonized in each tissue organ cell to form intractable subacute or chronic infection, is similar to tuberculosis, is a granulomatous disease which can affect any organ, and needs long-term chemotherapy to achieve clinical cure. Once diagnosed, antibiotics with strong cell penetration should be given in time for combined application, sufficient amount, long treatment course or multiple treatment courses. If the treatment is not standardized, the delay is usually caused. In a few cases, organic damages to bones and joints can be left, so that the movement of limbs is limited, and in some cases, sequelae of the central nervous system appear, thereby causing great physical and psychological pain and economic burden to patients. More serious can lead to patient death, the main cause of death being endocarditis, serious neurological complications, etc. The treatment of chronic cases caused by untimely and incomplete diagnosis and treatment is complex and has poor treatment effect. At present, no effective index for predicting the antibacterial treatment effect of brucellosis exists, and clinical diagnosis and treatment cannot be guided.

Disclosure of Invention

The invention aims to provide application of eosinophil level in predicting therapeutic effect of brucellosis, and particularly relates to evaluation of therapeutic effect of brucellosis patients by detecting eosinophil count and percentage.

A marker for detecting the treatment effect of brucellosis, wherein eosinophils are adopted as the marker.

Evaluating the treatment effect of the brucellosis patient according to the detected eosinophil count and percentage; the disease condition of the brucella patients is predicted according to the content or the change trend of the content of the blood eosinophils.

Use of a marker for detecting the therapeutic effect and predicting the condition of a patient suffering from brucella.

Use of a reagent for detecting a marker in the preparation of a reagent for assessing the therapeutic effect or predicting the condition of a patient suffering from brucella.

The reagent for detecting eosinophil is leukocyte differential dye liquor (STROMMATOLYSER-4 DS, FFS-800A).

Use of a method for detecting a marker for assessing the treatment effect or predicting the condition of a patient suffering from brucella.

The method for detecting eosinophils is flow cytometry.

Wherein the content of the first and second substances,

the detection marker is the detected eosinophil count and percentage.

The treatment effect refers to whether the body temperature of the patient is normal or not.

The disease condition of the patient with brucella is predicted according to the content of blood eosinophils or the change trend of the content of the blood eosinophils.

The method for predicting the treatment effect of brucellosis refers to judging the treatment effect by monitoring the blood eosinophil count and percentage of patients. The method is determined by dynamically monitoring blood routine during treatment of brucella patients.

The invention discloses for the first time: eosinophil count and proportion are reduced in brucella patients, and eosinophil count and proportion are gradually recovered after anti-infection treatment.

Drawings

FIG. 1 is a graph of eosinophil count and percentage levels before and after normothermia in a patient.

FIG. 2 is a graph of the patient's eosinophil count and percentage change during the course of treatment of the patient.

Detailed Description

For the purpose of facilitating understanding, the invention will be described in detail below with reference to specific drawings and examples. It is specifically intended that the specification and figures are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application. Such modifications and variations are intended to be included within the scope of the present invention.

The methods used in the following examples are conventional methods unless otherwise specified. Materials or reagents required in the following examples are commercially available unless otherwise specified.

Main apparatus and reagents: fully automatic blood analyzers (XE-2100, SYSMEX CORPORATION, Japan); diluent (cellack, PK-30L), sheath fluid (CELLSHEATH), basophilic hemolysin (STROMATOLYSER-FB, FBA-200A), leucocyte-sorting hemolysin (STROMATOLYSER-4DL, FFD-200A), leucocyte-sorting Stain (STROMATOLYSER-4DS, FFS-800A), nucleated erythrocyte Stain (STROMATOLYSER-NR, SNR-800), haemoglobin hemolysin (SULFOLYSER, SLS-220A), juvenile hemolysin (STROMATOLYSER-IM, SIM-220A), detergent (CELLCLEAN, CL-50), nucleated erythrosin (STROMATOLYSER-NR), reticulocyte diluent (RETSEARCH-II Dilution), reticulocyte Stain (RETSEARCH-II Stain). All reagents were from SYSMEX CORPORATION (Sysmex group).